Filing Analysis
Ibex Limited announced several board-level changes, including the reappointment of Shuja Keen to the Board and the appointment of Mingzhe (JJ) Zhuang as Lead Independent Director. The company is also restructuring its governance by appointing John Jones as Chair.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Shuja Keen appointed to fill a vacancy on the Board effective December 19, 2025; he previously served on the board from March 2018 to December 2024.
- John Jones appointed as Chair of the Board.
- Mingzhe (JJ) Zhuang appointed as Lead Independent Director and Chair of the Corporate Governance Committee.
- The governance changes are described as responsive to previously received shareholder feedback.
Ibex Limited held its 2025 Annual General Meeting on December 5, 2025, where shareholders approved several key proposals including director counts and auditor appointments. The filing also notes the withdrawal of one nominee from the board election process.
🚩 Red Flags
- One board nominee (Mohammed Khaishgi) withdrew prior to the meeting, creating a current vacancy.
📋 Key Facts
- Annual General Meeting held on December 5, 2025.
- Shareholders approved setting the maximum number of directors at eight.
- Seven nominees were elected to the Board of Directors.
- Deloitte & Touche LLP was re-appointed as the Company's auditor for the fiscal year ending June 30, 2026.
- The 2020 Long-Term Incentive Plan was amended and restated with shareholder approval.
- Mohammed Khaishgi withdrew his nomination for director for personal reasons (no disagreement reported).
Ibex Limited has established a formal Nominating Committee to address governance concerns raised by proxy advisory firms ISS and Glass Lewis. The committee consists of five independent directors and will oversee the nomination process for the upcoming annual meeting on December 5, 2025.
🚩 Red Flags
- Governance criticism from major proxy advisory firms (ISS and Glass Lewis) indicates previous deficiencies in board nomination processes.
📋 Key Facts
- Board established a formal Nominating Committee on November 20, 2025.
- Committee members appointed: Daniella Ballou-Aares (Chair), Karen Batungbacal, Fiona Beck, Patrick McGinnis, and Mingzhe (JJ) Zhuang.
- The move is intended to rectify perceived deficiencies in the nominating process identified by Institutional Shareholder Services Inc. (ISS) and Glass Lewis & Co., LLC.
- The Committee ratified prior actions taken by independent board members over the past year.
- Director nominees will be presented for election at the annual meeting on December 5, 2025.
IBEX Limited has filed an 8-K to announce its financial results for the first fiscal quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release issued on November 6, 2025.
📋 Key Facts
- Reporting period: First fiscal quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
IBEX Limited has filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended June 30, 2025. The filing serves as a formal announcement of the release of their periodic earnings data.
📋 Key Facts
- Financial results announced for Q4 and Fiscal Year ended June 30, 2025.
- Filing date: September 11, 2025.
- The report includes a press release as Exhibit 99.1.
IBEX Limited announced its third fiscal quarter financial results for the period ended March 31, 2025. Additionally, the Board of Directors authorized a $15 million share repurchase plan to commence on May 12, 2025.
📋 Key Facts
- Financial results for Q3 (ended March 31, 2025) were released via press release on May 8, 2025.
- Board authorized a share repurchase plan to commence May 12, 2025.
- The repurchase plan allows for up to $15 million of common stock over the next twelve months.
- Repurchases will be funded using existing cash balance.
IBEX Limited has filed an 8-K to announce its financial results for the second fiscal quarter ended December 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on February 6, 2025.
📋 Key Facts
- Reporting period: Second fiscal quarter ended December 31, 2024.
- Filing date: February 6, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- The company is an emerging growth company.
IBEX Limited has fully repaid a $25 million convertible promissory note issued to The Resource Group International Limited (TRGI) on November 19, 2024. The repayment was funded through existing lines of credit with HSBC.
🚩 Red Flags
- Significant related-party transaction: The $70M share purchase involved a convertible promissory note to TRGI, which was settled using bank credit lines rather than operational cash flow.
📋 Key Facts
- The Company paid in full the $25 million Seller Note on January 9, 2025.
- The note was originally issued to TRGI as part of a $70 million share purchase agreement (which included $45M cash and $25M in debt).
- Repayment was funded via lines of credit with HSBC Bank USA, National Association, and HSBC Bank Middle East Limited.
- The Seller Note has been officially terminated.
IBEX Limited experienced a significant board restructuring on December 31, 2024, involving the resignation of Shuja Keen and the revocation of five appointed directors by The Resource Group International Limited (TRGI). This resulted in the appointment of several 'Continuing Directors' to fill vacancies and the addition of Karen Batungbacal to the Board.
🚩 Red Flags
- Significant board instability: Multiple director departures/revocations occurring simultaneously on Dec 31, 2024.
- Conflict/Power Shift: The revocation of directors by TRGI suggests a significant shift in control or an ongoing dispute related to a purchase agreement dated Nov 19, 2024.
📋 Key Facts
- Shuja Keen resigned from the Board, including the Compensation and Nominating/Governance Committees, effective Dec 31, 2024.
- TRGI revoked appointments of five directors: Robert Dechant, Daniella Ballou-Aares, Mingzhe (JJ) Zhuang, Patrick McGinnis, and John Jones.
- The Board appointed the 'Continuing Directors' to fill vacancies created by TRGI's revocation.
- Karen Batungbacal was appointed as a director effective January 20, 2025; she has extensive leadership experience at Tenet Healthcare and UnitedHealth Group.
- Non-employee directors (except CEO Robert Dechant) receive an annual cash retainer of $75,000.
Ibex Limited held its 2024 annual general meeting of shareholders on December 5, 2024. Shareholders approved the maximum number of directors, elected three nominees to the Board, and reappointed Deloitte & Touche LLP as the company's auditor.
🚩 Red Flags
- Significant 'Against' votes for certain directors: Shuja Keen (4.2M against) and Mohammed Khaishgi (5.1M against), suggesting potential shareholder dissatisfaction with specific board members or governance direction.
📋 Key Facts
- Annual General Meeting held on December 5, 2024.
- Proposal 1: Shareholders approved setting the maximum number of directors at eight (14,255,011 votes 'For').
- Proposal 2: Election of three directors: Fiona Beck, Shuja Keen, and Mohammed Khaishgi.
- Proposal 3: Appointment of Deloitte & Touche LLP as auditor for the fiscal year ending June 30, 2025 (14,272,942 votes 'For').
- Voting results for director elections showed varying levels of opposition, notably Shuja Keen and Mohammed Khaishgi received significant 'Against' votes relative to their total tallies.
IBEX Limited entered into a significant share repurchase agreement with its controlling shareholder, The Resource Group International Limited (TRGI), for $70 million. The transaction involves a mix of cash and a $25 million convertible promissory note issued to the controlling shareholder.
🚩 Red Flags
- Related-party transaction: The company is transacting directly with its controlling shareholder (TRGI).
- Potential dilution: The $25 million convertible note allows the controlling shareholder to convert debt into equity during specific windows.
- Complex financing structure: Use of a non-dated convertible promissory note to fund a share repurchase from an insider/controller.
📋 Key Facts
- Company repurchased 3,562,341 common shares from TRGI on November 19, 2024.
- Total transaction value: $70 million ($45M cash, $25M convertible promissory note).
- The Seller Note (convertible note) carries a 7% annual interest rate payable monthly in arrears.
- TRGI retains ownership of 1,786,091 shares following the transaction.
- A call option was granted to IBEX allowing it to purchase any other shares beneficially owned by TRGI upon a change in control of TRGI within the next four years.
- The Seller Note has no fixed maturity date and terminates upon full prepayment or conversion.
IBEX Limited filed an 8-K to announce its financial results for the first fiscal quarter ended September 30, 2024. The filing serves as a formal notice of the earnings release issued on November 7, 2024.
📋 Key Facts
- Reporting period: First fiscal quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the financial results.
IBEX Limited has entered into new credit facilities with HSBC, replacing an existing $80 million facility from PNC Bank. The new arrangements include a $25 million US revolving credit facility and a $50 million UAE revolving loan facility.
🚩 Red Flags
- Replacement of a larger $80M facility with smaller segmented facilities ($25M US + $50M UAE) may indicate a restructuring of debt obligations or tighter liquidity management.
- New financial covenants (net leverage and fixed charge coverage) impose stricter operational requirements on the company.
📋 Key Facts
- Entered into a $25 million secured US revolving credit facility with HSBC Bank USA on October 29, 2024.
- US Facility interest rate: Term SOFR + 2% (or alternate base rate + 1%).
- Entered into a $50 million UAE post-shipment seller revolving loan facility via Ibex Global FZ-LLC with HSBC Bank Middle East Limited.
- UAE Facility interest rate: 3-month term SOFR + 2%.
- The new facilities replace the existing $80 million secured revolving credit agreement with PNC Bank, which was fully repaid and terminated on October 29, 2024.
- New agreements include financial covenants regarding total net leverage ratio and fixed charge coverage ratio.
IBEX Limited announced several changes to its Board of Directors, including the resignation of John Leone and the planned retirement of Gerard Kleisterlee. The company also appointed Fiona Beck to fill a vacancy and noted new appointments from TRGI.
🚩 Red Flags
- Multiple board departures in a single filing can sometimes signal internal shifts, though no disagreement was cited here.
📋 Key Facts
- John Leone resigned from the Board effective October 24, 2024.
- Gerard Kleisterlee intends to retire from the Board following the 2024 Annual General Meeting of Shareholders.
- Fiona Beck was appointed to fill Mr. Leone's vacancy and will serve on the Audit Committee.
- Patrick McGinnis has been appointed to the Board effective October 24, 2024.
- Mingzhe (JJ) Zhuang is appointed to the Board effective at the 2024 Annual Meeting of Shareholders.
- Non-employee directors receive an annual cash retainer of $75,000.
IBEX Limited has filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended June 30, 2024. The filing serves as a formal announcement of the earnings release issued on September 12, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended June 30, 2024.
- Announcement date: September 12, 2024.
- The filing includes a press release as Exhibit 99.1 regarding the financial results.
IBEX Limited announced its third fiscal quarter financial results for the period ended March 31, 2024. Additionally, the company disclosed a board-authorized share repurchase plan of up to $30 million.
📋 Key Facts
- Financial results for Q3 (ended March 31, 2024) were released on May 9, 2024.
- The Board authorized a Share Repurchase Plan on May 1, 2024.
- The repurchase program allows for up to $30 million of common stock over the next 12 months.
- Repurchases will be funded using existing cash balances.
IBEX Limited filed an 8-K to announce its financial results for the second fiscal quarter ended December 31, 2023. The filing serves as a formal notice that a press release containing these results was issued on February 8, 2024.
📋 Key Facts
- Reporting period: Second fiscal quarter ended December 31, 2023.
- Filing date: February 8, 2024.
- The company is an emerging growth company as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).